408 related articles for article (PubMed ID: 16556057)
1. Tumor acidity, chemoresistance and proton pump inhibitors.
De Milito A; Fais S
Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors may reduce tumour resistance.
De Milito A; Fais S
Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
[TBL] [Abstract][Full Text] [Related]
3. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
[TBL] [Abstract][Full Text] [Related]
4. Manipulating tumor acidification as a cancer treatment strategy.
McCarty MF; Whitaker J
Altern Med Rev; 2010 Sep; 15(3):264-72. PubMed ID: 21155627
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
6. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.
Chen M; Zou X; Luo H; Cao J; Zhang X; Zhang B; Liu W
Cell Biol Int; 2009 Sep; 33(9):1008-19. PubMed ID: 19501661
[TBL] [Abstract][Full Text] [Related]
7. Extracellular acidity as favouring factor of tumor progression and metastatic dissemination.
Calorini L; Peppicelli S; Bianchini F
Exp Oncol; 2012 Jul; 34(2):79-84. PubMed ID: 23013757
[TBL] [Abstract][Full Text] [Related]
8. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump.
Fan S; Niu Y; Tan N; Wu Z; Wang Y; You H; Ke R; Song J; Shen Q; Wang W; Yao G; Shu H; Lin H; Yao M; Zhang Z; Gu J; Qin W
Oncogene; 2013 Mar; 32(13):1682-90. PubMed ID: 22580606
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
De Milito A; Iessi E; Logozzi M; Lozupone F; Spada M; Marino ML; Federici C; Perdicchio M; Matarrese P; Lugini L; Nilsson A; Fais S
Cancer Res; 2007 Jun; 67(11):5408-17. PubMed ID: 17545622
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.
Fais S
J Intern Med; 2010 May; 267(5):515-25. PubMed ID: 20433578
[TBL] [Abstract][Full Text] [Related]
11. Targeting vacuolar H+-ATPases as a new strategy against cancer.
Fais S; De Milito A; You H; Qin W
Cancer Res; 2007 Nov; 67(22):10627-30. PubMed ID: 18006801
[TBL] [Abstract][Full Text] [Related]
12. A rationale for the use of proton pump inhibitors as antineoplastic agents.
De Milito A; Marino ML; Fais S
Curr Pharm Des; 2012; 18(10):1395-406. PubMed ID: 22360553
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
Adams DJ; Wahl ML; Flowers JL; Sen B; Colvin M; Dewhirst MW; Manikumar G; Wani MC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):145-54. PubMed ID: 16001167
[TBL] [Abstract][Full Text] [Related]
14. Myrtenal-induced V-ATPase inhibition - A toxicity mechanism behind tumor cell death and suppressed migration and invasion in melanoma.
Martins BX; Arruda RF; Costa GA; Jerdy H; de Souza SB; Santos JM; de Freitas WR; Kanashiro MM; de Carvalho ECQ; Sant'Anna NF; Antunes F; Martinez-Zaguilan R; Souad S; Okorokova-Façanha AL; Façanha AR
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):1-12. PubMed ID: 30279148
[TBL] [Abstract][Full Text] [Related]
15. Proton channels and exchangers in cancer.
Spugnini EP; Sonveaux P; Stock C; Perez-Sayans M; De Milito A; Avnet S; Garcìa AG; Harguindey S; Fais S
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2715-26. PubMed ID: 25449995
[TBL] [Abstract][Full Text] [Related]
16. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.
De Milito A; Canese R; Marino ML; Borghi M; Iero M; Villa A; Venturi G; Lozupone F; Iessi E; Logozzi M; Della Mina P; Santinami M; Rodolfo M; Podo F; Rivoltini L; Fais S
Int J Cancer; 2010 Jul; 127(1):207-19. PubMed ID: 19876915
[TBL] [Abstract][Full Text] [Related]
17. V-ATPase as an effective therapeutic target for sarcomas.
Perut F; Avnet S; Fotia C; Baglìo SR; Salerno M; Hosogi S; Kusuzaki K; Baldini N
Exp Cell Res; 2014 Jan; 320(1):21-32. PubMed ID: 24416789
[TBL] [Abstract][Full Text] [Related]
18. TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells.
Lozupone F; Borghi M; Marzoli F; Azzarito T; Matarrese P; Iessi E; Venturi G; Meschini S; Canitano A; Bona R; Cara A; Fais S
Oncogene; 2015 Oct; 34(40):5163-74. PubMed ID: 25659576
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.
Spugnini EP; Citro G; Fais S
J Exp Clin Cancer Res; 2010 May; 29(1):44. PubMed ID: 20459683
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments.
Li W; Sun X
Recent Pat Anticancer Drug Discov; 2018; 13(4):455-468. PubMed ID: 30173649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
